Logo Image
|Videos|October 21, 2022

Testing Responsibly: Assessing Pneumonia FilmArray Use

Author(s)Nina Cosdon

At IDWeek 2022, antimicrobial stewardship was front and center. However, not all tests are created equal.

The BioFire FilmArray Pneumonia Panel is a sample-to-answer assay, cleared by the US Food and Drug Administration (FDA). It enables the detection of viruses, atypical bacteria, bacteria, and antimicrobial resistance marker genes from lower respiratory tract specimens.

While it is vital to hinder antimicrobial resistance, the pneumonia FilmArray is a very expensive test. How can we ensure it is properly utilized?

Brittani Weichman, PharmD, is a PGY1 pharmacy resident at UnityPoint Health Meriter in Madison, Wisconsin. In an exclusive interview with Contagion, Weichman noted that her team’s aim in assessing this test was twofold: to determine whether it was used correctly, and if it was used unnecessarily.

This poster, "Assessment of Pneumonia FilmArray Use on the Impact on Antimicrobial De-escalation Within an Integrated Health System," was presented by Weichman at IDWeek 2022, held October 19-23, 2022, in Washington, D.C.

Related to this article

View more
Ceftriaxone Safety: Separating Signal From Risk
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Read more
Treatment of Latent Tuberculosis in a Trice
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Read more
Drawing Borders Around a Borderless Specialty
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Read more
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
Read more
A Review of Vibrio vulnificus: Clinical Presentation and Treatment
A Review of Vibrio vulnificus: Clinical Presentation and Treatment
Vibrio species are bacteria that live in saltwater environments. When ingested orally or through contact with open wounds, some species can cause severe life-threatening infections, particularly in those with high-risk conditions, such as liver disease. Here is a review of Vibrio vulnificus and the recommended antibiotic treatment.
Read more